Stock CARM CARISMA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.64 USD 0.00% Intraday chart for Carisma Therapeutics, Inc. +0.61% -44.03%
Apr. 11 BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target MT
Apr. 02 HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating MT

Evolution of the average Target Price on Carisma Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

97f82f35c4d486637a882.FDgySP8Llxa0nr07jmZAVG95hGPJ1Lpxz9X82fssCzw.OXoGGIVc0XSH1IkLuxEMHT4A3CGPl9kA-Jq4r81gSnZ5eUNlkE7TJ_Ozzg~62ef0b78828a26a08e0d6de9d1bf5d4c

Analyst Recommendations on Carisma Therapeutics, Inc.

BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target MT
HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating MT
Capital Starts Carisma Therapeutics at Overweight With $10 Price Target MT
HC Wainwright Adjusts Price Target on CARISMA Therapeutics to $11 From $10, Keeps Buy Rating MT
Evercore ISI Initiates CARISMA Therapeutics at Outperform With $12 Price Target MT
HC Wainwright Starts Carisma Therapeutics at Buy With $10 Price Target MT
Baird Initiates CARISMA Therapeutics at Outperform With $10 Price Target MT
SESEN BIO : Jefferies & Co Downgrades Sesen Bio to Hold From Buy, Adjusts PT to $1.50 From $6 MT
SESEN BIO : Canaccord Genuity Adjusts Sesen Bio PT to $3 From $7, Maintains Buy Rating MT
SESEN BIO : HC Wainwright Downgrades Sesen Bio to Neutral From Buy MT
SESEN BIO : Jefferies Adjusts Price Target for Sesen Bio to $6 From $3, Maintains Buy Rating MT
SESEN BIO : Canaccord Adjusts Sesen Bio's Price Target to $7 from $5, Keeps Buy Rating MT
SESEN BIO : HC Wainwright Adjusts Sesen Bio's Price Target to Street-High $8 From $2.25, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.64 USD
Average target price
8.4 USD
Spread / Average Target
+412.20%
High Price Target
10 USD
Spread / Highest target
+509.76%
Low Price Target
6 USD
Spread / Lowest Target
+265.85%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Carisma Therapeutics, Inc.

BTIG
HC Wainwright
Capital One Securities
Evercore ISI
Baird
Canaccord Genuity
Jefferies & Co.

Ratings for Carisma Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CARM Stock
  4. Consensus Carisma Therapeutics, Inc.